News | January 14, 2025
Odisha to implement AB PM-JAY scheme
The scheme is fully digitized and covers approximately 45% of India's population
The scheme is fully digitized and covers approximately 45% of India's population
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
Modi remarked that more than 20 illustrious research institutions such as IISc, IITs, CSIR and DBT-BRIC have played a major role in this research
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country
ICMR will continue to track trends in HMPV circulation throughout the year
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
Subscribe To Our Newsletter & Stay Updated
